Company news, research breakthroughs, and major announcements across industries.

Home/Science

Science

IDWeek 2026: Shionogi Presents U.S. Analysis of Real-World Data Showing Early Treatment Initiation with Fetroja®/Fetcroja® (cefiderocol) Improved Clinical Outcomes in Patients with Respiratory Infections

Group-brand-mark_V-Type_rgb_full-color_%281%29.jpg
Group-brand-mark_V-Type_rgb_full-color_%281%29.jpg

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) will present new data at IDWeek 2026 that reinforce the role of Fetroja®/Fetcroja® (cefiderocol), an innovative siderophore cephalosporin, in serious Gram-negative infections. Cefiderocol data highlights at IDWeek will include new U.S. real-world data demonstrating improved clinical outcomes with early cefiderocol treatment versus salvage ther...

  • PublishedOctober 21, 2026 · 8:00 AM
  • LocationOSAKA, Japan
  • IndustryScience
  • LanguageEN

Published by Business Wire. Read the original announcement for the full release.

Read the full announcement →

Latest from leading organizations

Explore recent announcements by organization